X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GSK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GSK PHARMA PANACEA BIOTECH/
GSK PHARMA
 
P/E (TTM) x -21.6 66.9 - View Chart
P/BV x 3.0 11.7 25.8% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 PANACEA BIOTECH   GSK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GSK PHARMA
Mar-17
PANACEA BIOTECH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1493,838 3.9%   
Low Rs822,637 3.1%   
Sales per share (Unadj.) Rs84.1354.2 23.8%  
Earnings per share (Unadj.) Rs-18.339.8 -46.0%  
Cash flow per share (Unadj.) Rs-6.742.9 -15.6%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs83.7236.9 35.3%  
Shares outstanding (eoy) m61.2584.70 72.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.49.1 15.0%   
Avg P/E ratio x-6.381.4 -7.7%  
P/CF ratio (eoy) x-17.275.5 -22.8%  
Price / Book Value ratio x1.413.7 10.1%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m7,074274,216 2.6%   
No. of employees `0002.84.7 58.5%   
Total wages/salary Rs m1,4494,830 30.0%   
Avg. sales/employee Rs Th1,874.16,387.0 29.3%   
Avg. wages/employee Rs Th527.01,028.3 51.2%   
Avg. net profit/employee Rs Th-407.7717.1 -56.9%   
INCOME DATA
Net Sales Rs m5,15430,000 17.2%  
Other income Rs m100728 13.7%   
Total revenues Rs m5,25430,728 17.1%   
Gross profit Rs m-7664,190 -18.3%  
Depreciation Rs m711263 270.3%   
Interest Rs m1,5030-   
Profit before tax Rs m-2,8814,655 -61.9%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771457 387.5%   
Tax Rs m171,744 1.0%   
Profit after tax Rs m-1,1213,368 -33.3%  
Gross profit margin %-14.914.0 -106.5%  
Effective tax rate %-0.637.5 -1.6%   
Net profit margin %-21.811.2 -193.8%  
BALANCE SHEET DATA
Current assets Rs m3,81016,742 22.8%   
Current liabilities Rs m8,3657,202 116.1%   
Net working cap to sales %-88.431.8 -277.9%  
Current ratio x0.52.3 19.6%  
Inventory Days Days15652 300.5%  
Debtors Days Days6721 323.5%  
Net fixed assets Rs m14,4808,635 167.7%   
Share capital Rs m61847 7.2%   
"Free" reserves Rs m90319,222 4.7%   
Net worth Rs m5,12720,069 25.5%   
Long term debt Rs m5,83210 58,317.0%   
Total assets Rs m19,43330,038 64.7%  
Interest coverage x-0.9NM-  
Debt to equity ratio x1.10 228,260.7%  
Sales to assets ratio x0.31.0 26.6%   
Return on assets %2.011.2 17.5%  
Return on equity %-21.916.8 -130.3%  
Return on capital %3.625.5 14.3%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,539528 291.5%   
Fx outflow Rs m9427,193 13.1%   
Net fx Rs m597-6,665 -9.0%   
CASH FLOW
From Operations Rs m5992,360 25.4%  
From Investments Rs m-4383,008 -14.6%  
From Financial Activity Rs m-303-5,108 5.9%  
Net Cashflow Rs m-141260 -54.3%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.6 10.2 5.9%  
FIIs % 1.3 23.8 5.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 15.4 153.2%  
Shareholders   10,259 102,036 10.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS